We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Analysis of Molecular Diagnostics Business Published

By LabMedica International staff writers
Posted on 10 Feb 2014
Print article
A six-month analysis of the fast-growing molecular diagnostics in vitro diagnostic (IVD) test sector has been published by Kalorama Information
(New York, NY, USA).

Molecular diagnostics is becoming a dominant platform in clinical medicine and it represents one of the fastest growing segments of the diagnostics market. In light of the amount of activity in test development and the regulatory and reimbursement challenges in 2013, the emphasis of the report is on the last 6 months of 2013, July–December. The report provides a breakdown of key market segments for molecular diagnostic markets in world regions, including developed nations and emerging nations.

In the six-month period, trends and developments are highlighted that presage the evolution of molecular tests and technologies. The combination of consumer demand, technological advances, and market forces created a dynamic, energetic, and fast-moving environment for new tests and companies.

Although focused on the developments of the last six months, coverage is substantial. The Kalorama report provides current market size and forecasts for Molecular Diagnostic Segments, including microbiology, histology, blood screening, prenatal, coagulation, inherited diseases, tissue typing, and cancer. A breakdown of key market segments for molecular diagnostic markets in world regions, including developed nations and emerging nations is provided.

In addition the following important trend information is provided: Selected Sequencing-Based Innovations July-December 2013, Selected Molecular Diagnostics collaborations, July-December 2013, Selected Molecular Diagnostics Licensing Agreements, July-December 2013, Selected Molecular Diagnostics Distribution Agreements, July-December 2013, Regulatory and Reimbursement Update and Molecular Test Revenues of the Top Companies, 2012-2013.

Market analysis in this report covers world markets for in vitro diagnostics, but there is a bias toward the developed areas of the globe—North America and Western Europe. However, public health and infectious disease are a growing global problem and where possible the report covers IVD products related to the globalization of diseases. The information presented in the Kalorama report is derived primarily from company reports and other publicly available information published by government and medical organizations.

Related Links:
Kalorama Information




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The new blood test identifies key biomarkers of osteoarthritis (Photo courtesy of Shutterstock)

Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays

Osteoarthritis (OA) is the most prevalent form of arthritis, impacting millions worldwide and resulting in significant economic and social costs. Although no cure exists currently, the effectiveness of... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Sampler device could revolutionize sample collection for diagnostic tests (Photo courtesy of ReadyGo Diagnostics)

First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.